食管癌放化疗期间严重淋巴细胞减少:预测模型的外部验证
本研究纳入219例接受CROSS或extended-CROSS方案放化疗的食管癌患者,发现4级淋巴细胞减少发生率分别为11%和33%(p<0.001)。预测模型外部区分度良好(c-statistic 0.80),校准在CROSS中差但在extended-CROSS中尚可,校正后一致性尚可。发生4级淋巴细胞减少患者中位总生存期显著更短(12.7 vs 42.5个月,p=0.045)。
要点
- CROSS方案放化疗期间4级淋巴细胞减少发生率为11%,extended-CROSS为33%。
- 预测模型外部区分度良好,c-statistic为0.80(95%CI 0.70-0.89)。
- 发生4级淋巴细胞减少患者中位总生存期显著缩短(12.7 vs 42.5个月)。
核心结论
- extended-CROSS方案放化疗期间4级淋巴细胞减少发生率显著高于CROSS方案。
- 预测模型在CROSS方案背景下外部区分度良好,可用于识别高风险患者。
研究设计与样本
- 回顾性纳入2014至2019年接受放化疗的食管癌患者219例。
- 176例(80%)接受CROSS方案(计划放疗剂量41.4 Gy),43例(20%)接受extended-CROSS方案(50.4 Gy),均同步卡铂和紫杉醇化疗。
主要发现
- 4级淋巴细胞减少(淋巴细胞最低值<0.2 µL)发生率在CROSS组为11%,extended-CROSS组为33%(p<0.001)。
- 模型外部区分度c-statistic为0.80(95%CI 0.70-0.89)。
- 模型外部校准在CROSS组差,在extended-CROSS组尚可;经截距校正后观察风险与预测风险一致性尚可。
- 有和无4级淋巴细胞减少患者的中位总生存期分别为12.7个月和42.5个月(p=0.045)。
关键数值与推荐
- 4级淋巴细胞减少定义依据CTCAE v5.0,即淋巴细胞计数最低值<0.2 µL。
- CROSS方案计划放疗剂量为41.4 Gy,extended-CROSS方案为50.4 Gy。
临床怎么用
- 预测模型可用于识别接受CROSS方案放化疗的食管癌患者中4级淋巴细胞减少高风险者。
- 高风险患者可能适合接受减轻淋巴细胞减少的策略。
局限性
- 模型外部校准在CROSS组差,需截距校正后一致性才尚可。
- 本研究为回顾性设计,样本量有限(219例),extended-CROSS组仅43例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of grade 4 lymphopenia in patients treated with chemoradiotherapy (CRT) according to Chemoradiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) regimen is unclear. The primary aim was to determine the incidence of grade 4 lymphopenia during CROSS for esophageal cancer. Secondary aims were to externally validate a prediction model for grade 4 lymphopenia and compare overall survival between patients with and without grade 4 lymphopenia. METHODS: Patients who underwent CRT for esophageal cancer between 2014 and 2019 were eligible for inclusion. Patients with a planned radiation dose of 41.4 Gy (CROSS) or 50.4 Gy ("extended-CROSS") and concurrent carboplatin and paclitaxel were included. The primary outcome was the incidence of grade 4 lymphopenia during CRT defined according to Common Terminology Criteria for Adverse Events version 5.0 (i.e. lymphocyte count nadir < 0.2 µL). The secondary outcome measures were the prediction model's external performance (i.e. discrimination and calibration). Overall survival for patients with versus without grade 4 lymphopenia was compared using Kaplan-Meier analysis. RESULTS: A total of 219 patients were included of whom 176 patients (80%) underwent CROSS and 43 patients (20%) extended-CROSS. The incidence of grade 4 lymphopenia was 11% in CROSS and 33% in extended-CROSS (p < 0.001). External discrimination yielded a c-statistic of 0.80 (95% confidence interval: 0.70-0.89). External calibration of the model was poor in CROSS but fair in extended-CROSS. Adjusted calibration using intercept correction (adjusted for the lower a-priori risk for grade 4 lymphopenia in CROSS) showed fair agreement between the observed and predicted risk for grade 4 lymphopenia. Median overall survival in patients with versus without grade 4 lymphopenia was 12.7 versus 42.5 months (p = 0.045). CONCLUSION: The incidence of grade 4 lymphopenia is significantly higher in esophageal cancer patients receiving extended-CROSS compared to those receiving CROSS. The prediction model demonstrated good external performance in the setting of the CROSS-regimen and could be used to identify patients at high-risk for grade 4 lymphopenia who might be eligible for lymphopenia-mitigating strategies.
引用
- Kroese TE, Jairam J, Ruurda JP, et al. Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. Radiother Oncol. 2021. PMID: 34453954. doi:10.1016/j.radonc.2021.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。